Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HANS H HERFARTH

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1538246574
CMS profile
748946
Location
CHAPEL HILL, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$10,664.39

10 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $10,600.00 8
Food and Beverage $64.39 2

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Gilead Sciences, Inc. $10,600.00 8
Takeda Pharmaceuticals U.S.A., Inc. $48.70 1
AbbVie, Inc. $15.69 1

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HANS H HERFARTH

NPI 1538246574 · CMS profile ID 748946

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

CHAPEL HILL, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538246574?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HANS H HERFARTH, NPI 1538246574, CMS profile ID 748946. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538246574?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). HANS H HERFARTH, NPI 1538246574, CMS profile ID 748946. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538246574?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
HANS H HERFARTH, NPI 1538246574, CMS profile ID 748946, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1538246574?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

10 matching records · $10,664.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 10 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–10 of 10.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $1,000.0012/16/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679259239 CMS
Gilead Sciences, Inc. $1,000.0012/16/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679259241 CMS
Gilead Sciences, Inc. $2,000.0012/16/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679259249 CMS
AbbVie, Inc. $15.6911/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648089663 CMS
Gilead Sciences, Inc. $1,000.0009/04/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679259235 CMS
Gilead Sciences, Inc. $1,600.0009/04/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679259237 CMS
Gilead Sciences, Inc. $1,200.0008/28/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679259232 CMS
Gilead Sciences, Inc. $1,400.0005/20/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679259229 CMS
Takeda Pharmaceuticals U.S.A., Inc. $48.7005/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682107973 CMS
Gilead Sciences, Inc. $1,400.0004/22/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679259219 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,664.39 10
PY2020 $19,041.44 14
PY2021 $7,950.00 5
PY2022 $5,950.00 3
PY2023 $3,236.00 3
PY2024 $17,266.46 16
PY2025 $13,500.00 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,575.00 2
PY2025 Principal investigator $12,323.55 21
PY2024 Recipient $319,533.00 4
PY2024 Principal investigator $59,545.89 24
PY2023 Principal investigator $224,917.53 43
PY2022 Principal investigator $370,819.65 53
PY2021 Principal investigator $392,748.05 56
PY2020 Principal investigator $481,918.70 51
PY2019 Recipient $4,200.00 1
PY2019 Principal investigator $373,860.96 46

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AbbVie Inc. $1,465.60 12/21/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
M14-327 No dispute reported 06/30/2026 721201519
Principal investigator 1 Janssen Research & Development, LLC $7,385.36 12/14/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 719529009
Principal investigator 1 Roche Products Limited $4,212.00 12/10/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 857153501
Principal investigator 1 Roche Products Limited $750.00 12/03/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 857153415
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,249.70 12/01/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB SUBCUTANEOUS AS MAINTENANCE THERAPY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 737093463
Principal investigator 1 AbbVie Inc. $8,115.20 11/27/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
M14-327 No dispute reported 06/30/2026 721197037
Principal investigator 1 Janssen Research & Development, LLC $12,086.96 11/26/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 719529007
Principal investigator 1 AbbVie Inc. $3,726.00 11/17/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
M14-327 No dispute reported 06/30/2026 721195987
Principal investigator 1 Roche Products Limited $1,758.60 11/12/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 857153409
Principal investigator 1 AbbVie Inc. $1,500.00 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
M14-327 No dispute reported 06/30/2026 721194861
Principal investigator 1 Janssen Research & Development, LLC $1,434.00 10/26/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 719529005
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $8,201.33 10/20/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT TRIAL TO ASSESS THE EFFICACY AND SAFETY OF ORALLY ADMINISTERED OPS-2071 FOR 12 WEEKS IN SUBJECTS WITH CROHNS DISEASE SHOWING SYMPTOMS OF ACTIVE INFLAMMATION DESPITE ONGOING TREATMENT No dispute reported 06/30/2026 748805663
Principal investigator 1 Roche Products Limited $2,691.00 10/15/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 857153495
Principal investigator 1 PFIZER INC. $162,000.00 10/12/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA
TOFACITINIB IN UC REAL LIFE COHORT No dispute reported 06/30/2026 742880621
Principal investigator 1 AbbVie Inc. $1,414.40 09/28/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
M14-327 No dispute reported 06/30/2026 721187161
Principal investigator 1 Janssen Research & Development, LLC $7,336.36 09/28/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 719529003
Principal investigator 1 Roche Products Limited $18,854.10 09/22/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 857153491
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,046.00 09/15/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EARLY PROOF OF CONCEPT OF TAK-018 FOR THE PREVENTION OF POSTOPERATIVE CROHN'S DISEASE RECURRENCE No dispute reported 06/30/2026 737088069
Principal investigator 1 AbbVie Inc. $8,000.00 09/01/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
M14-327 No dispute reported 06/30/2026 721184497
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 08/31/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 719529001
Principal investigator 1 AbbVie Inc. $422.40 07/29/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
M14-327 No dispute reported 06/30/2026 721177239
Principal investigator 1 Janssen Research & Development, LLC $3,494.00 07/24/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 719528999
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,752.00 07/22/2020 Non-covered Recipient Entity
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ENTYVIO (VEDOLIZUMAB IV) IN THE TREATMENT OF CHRONIC POUCHITIS (EARNEST) No dispute reported 06/30/2026 737085575
Principal investigator 1 RedHill Biopharma Inc. $2,200.00 07/16/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
AN OPEN LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF FIXED-DOSE COMBINATION RHB-104 IN SUBJECTS WITH ACTIVE CROHN'S DISEASE DESPITE 26 WEEKS OF PARTICIPATION IN THE MAP US RHB-104-01 STUDY No dispute reported 06/30/2026 719675839
Principal investigator 1 RedHill Biopharma Inc. $2,030.00 07/16/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
AN OPEN LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF FIXED-DOSE COMBINATION RHB-104 IN SUBJECTS WITH ACTIVE CROHN'S DISEASE DESPITE 26 WEEKS OF PARTICIPATION IN THE MAP US RHB-104-01 STUDY No dispute reported 06/30/2026 719675843
Principal investigator 1 AbbVie Inc. $6,585.60 07/06/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
M14-327 No dispute reported 06/30/2026 721174921
Principal investigator 1 Janssen Research & Development, LLC $6,052.36 06/19/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 719528995
Principal investigator 1 Janssen Research & Development, LLC $1,368.00 06/01/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 719528997
Principal investigator 1 AbbVie Inc. $2,393.60 05/28/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
M14-327 No dispute reported 06/30/2026 721168377
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 05/28/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 719528993
Principal investigator 1 AbbVie Inc. $727.20 05/07/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
M14-327 No dispute reported 06/30/2026 721165641
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 04/27/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 719528989
Principal investigator 1 Janssen Research & Development, LLC $1,434.00 04/27/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 719528991
Principal investigator 1 AbbVie Inc. $1,350.40 03/30/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
M14-327 No dispute reported 06/30/2026 721158699
Principal investigator 1 Janssen Research & Development, LLC $4,877.00 03/27/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 719528981
Principal investigator 1 AbbVie Inc. $6,446.80 03/05/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
M14-327 No dispute reported 06/30/2026 721154855
Principal investigator 1 AbbVie Inc. $2,700.80 03/05/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
M14-327 No dispute reported 06/30/2026 721154857
Principal investigator 1 Janssen Research & Development, LLC $1,991.00 02/27/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 719528983
Principal investigator 1 PFIZER INC. $92,000.00 02/24/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA
TOFACITINIB IN UC REAL LIFE COHORT No dispute reported 06/30/2026 742880619
Principal investigator 1 Eli Lilly and Company $165.00 02/10/2020 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A MULTICENTER LONG-TERM EXTENSION STUDY OF 104 WEEKS INCLUDING A DOUBLE BLIND PLACEBO CONTROLLED 40 WEEK RANDOMIZED WITHDRAWAL RETREATMENT PERIOD TO EVALUATE THE MAINTENANCE OF TREATMENT EFFECT OF IXEKIZUMAB LY2439821 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 728725915
Principal investigator 1 Eli Lilly and Company $311.67 02/10/2020 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 728726135
Principal investigator 1 Eli Lilly and Company $311.67 02/10/2020 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A MULTICENTER, OPEN-LABEL, POST MARKETING CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH GENERALIZED PUSTULAR PSORIASIS AND ERYTHRODERMIC PSORIASIS No dispute reported 06/30/2026 728727267
Principal investigator 1 Eli Lilly and Company $311.67 02/10/2020 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF LY2439821 IN CHINESE PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 728732165
Principal investigator 1 Janssen Research & Development, LLC $3,616.32 02/07/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 719528985
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,168.00 01/31/2020 Non-covered Recipient Entity
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ENTYVIO (VEDOLIZUMAB IV) IN THE TREATMENT OF CHRONIC POUCHITIS (EARNEST) No dispute reported 06/30/2026 737069067
Principal investigator 1 Janssen Research & Development, LLC $3,659.00 01/27/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 719528987
Principal investigator 1 PFIZER INC. $62,000.00 01/13/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA
EFFICACY OF TOFACITINIB IN PATIENTS WITH UC No dispute reported 06/30/2026 742855227
Principal investigator 1 AbbVie Inc. $1,465.60 01/03/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
M14-327 No dispute reported 06/30/2026 721144509
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,670.00 01/02/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB SUBCUTANEOUS AS MAINTENANCE THERAPY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 737067153
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $750.00 01/02/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB SUBCUTANEOUS AS MAINTENANCE THERAPY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 737067155
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,438.00 01/02/2020 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB SUBCUTANEOUS AS MAINTENANCE THERAPY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 737067171